Last Stage of Trials for the Regeneron COVID-19 Cure

Last Stage of Trials for the Regeneron COVID-19 Cure

Published: 08-Jul-2020 | Published By: Market Research Store

Regeneron, American pharmaceutical firm, made the announcement that they are ready to enter the last stage of investigating whether their drug is useful for treating and preventing COVID-19. The last stage will be dealing with the human trials.

REGN-COV2 drug combines two antibodies, which helps in blocking the coronavirus' spike protein that invades the cells of the human beings. The drug has moved to the final stage, i.e., Phase 3 trial were it will be determined whether the drug is capable to prevent the infection among the people who have lately had an exposure to the virus, for instance, through personal contact with a family member. 

Around 2,000 patients from the US are enrolled in this trial, which is run in cooperation with NIAID. George Yancopoulos, Regeneron President, commented that their collaboration with NIAID for studying about the REGN-COV2 drug was a pleasure as it helped them in further preventing the virus spread. Very soon the vaccine for the coronavirus infection will be available in the market. 

Furthermore, there was another announcement made by Regeneron that they were also checking for the drug’s capability on treating non-hospitalized and hospitalized patients’ suffering from coronavirus. 

There will be an involvement of approximately 1,050 patients that are not hospitalized and 1,850 which are hospitalized in the Chile, Mexico, Brazil, and the US. The first round of information will be available by end of year.  

The scientists from the Regeron made evaluations of large number of antibodies that were harvested from humans and genetically modified mice. In this there were two identifications found that were most effective against SARS-CoV-2 virus and they did not compete against themselves.

Multi-antibody approach is used by the company for reducing the chance of virus mutations for avoiding the blocking of the single antibody. This approach is mentioned in detail in the latest study published in Science. 

The Market Research Store has published report on the global disease control and prevention vaccine market. The report consists of all the important information and statistics about the market.